Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This in-silico study identified several compounds as potential Vitamin D Receptor agonists, with Dolichosterone showing the strongest binding energy.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

This review of 355 articles found that apigenin, a compound found in many plants and vegetables, is mainly researched for its anti-inflammatory, neuroprotective, and anti-cancer properties, with enhanced efficacy when combined with allopathic drugs.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

In this study, in silico screening and molecular simulations identified β-sitosterol and brassicasterol as stable potential inhibitors of 5α-reductase1, suggesting they could be explored for androgenic alopecia treatment.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

This study found that chronic high dosages of 2-(difluoromethyl)-dl-ornithine caused various toxicities in rats and dogs, with some effects potentially minimized at lower dosages.

This study found that unripe Rubus occidentalis extracts may inhibit benign prostatic hyperplasia development in a rat model by reducing prostate weight and androgen-related gene expression.

This study found that 1′S-1′-acetoxychavicol acetate from Alpinia galanga inhibits Nox isozymes and suppresses testosterone-induced hair loss in a mouse model of androgenetic alopecia.

This article discusses ongoing and planned clinical chemoprevention trials for various agents and combinations but reports no new results; it highlights promising new agents and the evolving focus on molecular pathways.

This study by Gao et al. reports that two nonsteroidal selective androgen receptor modulators, S1 and S4, demonstrated tissue-selective actions in rats, suppressing prostate growth while maintaining muscle growth without altering hormone levels.

This article discusses the potential mechanism by which 5α-reductase inhibitors might offer protection against SARS-CoV-2, emphasizing possible roles of dehydroepiandrosterone and its impact on nitric oxide bioavailability, but reports no new experimental results.

In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

This study found that fluconazole induced early hair follicle resting phase (telogen effluvium) in rats, without changing retinoic acid levels in rats or human patients, suggesting further investigation into fluconazole's hair loss mechanism is needed.

This study suggests that RORα, RORβ, and RORγ mRNA expression in cashmere goat skin is related to different stages of hair follicle development, indicating a possible role in cycled cashmere growth.

This review discusses preclinical and clinical chemoprevention research for several cancers, noting challenges in effectiveness and toxicity, and emphasizes the need for further trials.

This study found that rice bran ash extract and orthosilicic acid both increased melanin synthesis and related protein expression in melanocytes, suggesting potential therapeutic use for melanin deficiency.

In this study, researchers using molecular docking techniques found that 12-Methoxy carnosic acid from rosemary shows promising potential as a natural inhibitor of the 5 alpha reductase enzyme, which is involved in hair loss, suggesting its efficacy compared to finasteride.

This study found that manipulating 5αR2 activity in human hepatocytes in vitro can regulate lipogenesis, with potential clinical implications for patients taking 5αR inhibitors.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

This Swedish cohort study found no association between the use of anti-androgenic 5α-reductase inhibitors and improved 5-year all-cause or disease-specific mortality in oesophago-gastric cancer patients, challenging the hypothesis that these drugs enhance survival outcomes.

This study found that in men with sexual dysfunction, use of 5ARI may reduce sexual drive and spontaneous erections without worsening pre-existing erectile or ejaculatory issues.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

In this study, fraction No. 3 of Oryza sativa bran extract demonstrated high unsaturated fatty acid content and significant 5α-reductase inhibition, suggesting potential for developing anti-androgenic alopecia products.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study suggests that Achyranthis Radix ethanol extract may promote hair growth by increasing cell proliferation and protein expression in human hair dermal papilla cells.